[{"id":"35e608cc-539c-4ac1-a89a-c289c5e8a0c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01522404","created_at":"2021-01-18T06:24:18.792Z","updated_at":"2024-07-02T16:36:57.820Z","phase":"Phase 2","brief_title":"Effects of Atomoxetine in Mild Cognitive Impairment","source_id_and_acronym":"NCT01522404","lead_sponsor":"Emory University","biomarkers":" IL1A • APOE • CYP2D6","pipe":"","alterations":" ","tags":["IL1A • APOE • CYP2D6"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 10/31/2017","primary_completion_date":" 10/31/2017","study_txt":" Completion: 06/30/2018","study_completion_date":" 06/30/2018","last_update_posted":"2019-07-23"}]